

DAFTAR PUSTAKA

- Abba, M., Patil, N., & Allgayer, H. (2014). MicroRNAs in the Regulation of MMPs and Metastasis. *Cancers*, **6**(2), pp.625–645. <https://doi.org/10.3390/cancers6020625>
- American Cancer Society. (2014). Cancer Facts & Figures 2014. [ebook] Cancer.org. Available at: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2014/cancer-facts-and-figures-2014.pdf> [Accessed 23 Aug. 2018].
- Amos, C.I., Xu, W., Spitz, M. R. (1999). Is there a genetic basis for lung cancer susceptibility? *Recent Results Cancer Res*, 151: 3–12.
- Anindo, M. I. K., & Yaqinuddin, A. (2012). Insights into the potential use of microRNAs as biomarker in cancer. *International Journal of Surgery*, **10**(9), pp.443–449. <https://doi.org/10.1016/j.ijssu.2012.08.006>
- Anttila, S., Hakkola, J., Tuominen, P., et al. (2003). Methylation of cytochrome P4501A1 promoter in the lung is associated with tobacco smoking. *Cancer Res*, 63:8623–8628.
- Apama, S., Suresh, M., C, Babu., Govind, K Babu., Suresh, TM. (2015). Hyperleukocytosis, an unusual paraneoplastic manifestation of lung cancer: Case report and review of literature. *J Can Res Ther*, 11:699. <https://www.cancerjournal.net/article.asp?issn=09>.
- Bedard, P. L., Hansen, A. R., Ratain, M. J., et al. (2013). Tumour heterogeneity in the clinic. *Nature*, 501:355–64. <https://doi.org/10.1038/nature12627>
- Berezikov, E., Guryev, V., van de Belt, J., Wienholds, E., Plasterk, R. H., & Cuppen, E. (2005). Phylogenetic shadowing and computational identification of human microRNA genes. *Cell*, **120**(1), pp.21–24. <https://doi.org/10.1016/j.cell.2004.12.031>
- Bosse, Y., Amos, C. I. (2017). A decade of GWAS results in lung cancer. *Cancer Epidemiol Biomarkers Prev*, 27(4):363–379. Doi: 10.1158/1055-9965.EPI-16-0794.
- Botstein, D., Risch, N. (2003). Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. *Nat Genet*, 33 Suppl:228–237.
- Bowman, B. T. (2017). Electrolyte disorders associated with cancer. *Journal of Onco-Nephrology*, **1**(1), pp.30–35. <https://doi.org/10.5301/jo-n.5000004>

- Burdett, S., Johson, D. H., Stewart, L., Tierney, J., Le Pechoux, C. (2007). Supportive care and chemotherapy vs supportive care alone in advanced NSCLC: A meta analyses using individual patient data (IPD) from randomized controlled trials. *J Thorac Oncol*, 2:S337.
- Campbell, J. D., Alexandrov, A., Kim, J., et al. (2016). Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. *Nat Genet*, 48: 607-16.
- Cappuzzo, F., Toschi, L., Domenichini, I., et al. (2005). HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. *Br J Cancer*, 93: 1334–1340.
- Carlsten, C., Sagoo, G. S., Frodsham, A. J., Burke, W., Higgins, J. P. (2008). Glutathione S-Transferase M1 (GSTM1) Polymorphisms and Lung Cancer: A Literature-based Systematic HuGE Review and Meta-Analysis. *Am J Epidemiol*.
- Caro, J. J., Salas, M., Ward, A., & Goss, G. (2001). Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. *Cancer*, **91**(12), pp.2214–2221. [https://doi.org/10.1002/1097-0142\(20010615\)91:12<2214::AID-CNCR1251>3.0.CO;2-P](https://doi.org/10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P)
- Chalhoub, N., & Baker, S. J. (2009). PTEN and the PI3-Kinase Pathway in Cancer. *Annual Review of Pathology*, **4**, pp.127–150. <https://doi.org/10.1146/annurev.pathol.4.110807.092311>
- Ciuffreda L. M. J., Milella M. (2009). Signaling intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK pathways) as therapeutic targets for anti-cancer and anti angiogenesis treatments. *Curr Signal Transduct Ther*, **4**, pp.130-43.
- Ciuffreda L., Di Sanza C., Cesta Incani U., et al. (2012). The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. *J Mol Med*, **90**, pp.667-79.
- Costanzo, R., Montanino, A., Di Maio, M., Piccirillo, M. C., Sandomenico, C., Giordano, P., et al. (2013). Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. *Expert Review of Anticancer Therapy*, **13**(10), pp.1207-1218. <https://doi.org/10.1586/14737140.2013.845092>
- Croce, C. M. (2009). Causes and consequences of microRNA dysregulation in cancer. *Nature Reviews. Genetics*, **10**(10), pp.704–714. <https://doi.org/10.1038/nrg2634>

- Crowley E., Di Nicolantonio F., Loupakis F., et al. (2013). Liquid biopsy: monitoring cancer-genetics in the blood. *Nat Rev Clin Oncol*, 10:472-84. <https://doi.org/10.1038/nrclinonc.2013.110>
- Dacic S., Kelly L., Shuai Y., Nikiforova M. N. (2010). miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. *Mod Pathol*, **23**, pp. 1577-82.
- Delmotte, P., Martin, B., Paesmans, M., Berghmans, T., Mascaux, C., Meert, A. P., et al. (2002). VEGF et survie des patients atteints d'un cancer pulmonaire: Revue systématique avec méta-analyse. *Revue des Maladies Respiratoires*, [online] **19**(5), pp.577–584. Available at: <https://www.em-consulte.com/rmr/article/151433/> [Accessed 02 July 2018]
- Denison M. S., Rogers J. M., Rushing S. R., Jones C. L., Tetangco S. C., Heath-Pagliuso S. (2002). Analysis of the aryl hydrocarbon receptor (AhR) signal transduction pathway. *Curr Protoc Toxicol*, Chapter 4:Unit4.8.
- Detassis, S., Grasso, M., Del Vescovo, V., & Denti, M. A. (2017). MicroRNAs Make the Call in Cancer Personalized Medicine. *Frontiers in Cell and Developmental Biology*, **5**, p.86. <https://doi.org/10.3389/fcell.2017.00086>
- Di Leva, G., Garofalo, M., & Croce, C. M. (2014). MicroRNAs in cancer. *Annual Review of Pathology*, **9**, pp.287–314. <https://doi.org/10.1146/annurev-pathol-012513-104715>
- Diaz L. A., Jr, Bardelli A. (2014). Liquid biopsies: genotyping circulating tumor DNA. *J Clin Oncol*, 32:579-86. <https://doi.org/10.1200/JCO.2012.45.2011>
- Diaz L. A., Jr, Williams R. T., Wu J., et al. (2012). The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. *Nature*, 486:537-40.
- Donnem, T., Eklo, K., Berg, T., Sorbye, S. W., Lonvik, K., Al-Saad, S., et al. (2011). Prognostic Impact of MiR-155 in Non-Small Cell Lung Cancer Evaluated by in Situ Hybridization. *Journal of Translational Medicine*, **9**, p.6. <https://doi.org/10.1186/1479-5876-9-6>
- Douben P. (2003). PAHs: An Ecotoxicological Perspective. Hoboken, NJ: John Wiley & Sons.
- Douillard J. Y., Ostoros G., Cobo M., et al. (2014). Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. *J Thorac Oncol*, 9:1345-53. <https://doi.org/10.1097/JTO.0000000000000263>
- Du, X., Qi, F., Lu, S., Li, Y., Han, W. (2018). Nicotine upregulates FGFR2 and RB1 expression and promotes non-small cell lung cancer cell proliferation

and epithelial-to-mesenchymal transition via downregulation of miR-99b and miR-192. *Biomed Pharmacother*, 101: 656-662. Doi: 10.1016/j.biopha.2018.02.113

Eberhard DA, Johnson BE, Amler LC, et al. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. *J Clin Oncol*, 23: 5900–5909.

Faraoni, I., Antonetti, F. R., Cardone, J., & Bonmassar, E. (2009). miR-155 gene: a typical multifunctional microRNA. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*, 1792(6), pp.497–505. <https://doi.org/10.1016/j.bbadis.2009.02.013>

Fearon, K. C. H., Glass, D. J., & Guttridge, D. C. (2012). Cancer cachexia: mediators, signaling, and metabolic pathways. *Cell Metabolism*, 16(2), pp.153-166. <https://doi.org/10.1016/j.cmet.2012.06.011>

Fisher, R., Pusztai, L., Swanton, C. (2013). Cancer heterogeneity: implications for targeted therapeutics. *Br J Cancer*, 108: 479-85.

Frank, C., Detterbeck, . (2017). The eighth edition TNM stage classification for lung cancer: what does it mean on main street. *J Thorac Cardiovasc Surg*, 155:356-9. [https://www.jtcvs.org/article/S0022-5223\(17\)321](https://www.jtcvs.org/article/S0022-5223(17)321).

Friedman, R. C., Farh, K. K.-H., Burge, C. B., & Bartel, D. P. (2009). Most mammalian mRNAs are conserved targets of microRNAs. *Genome Research*, 19(1), pp.92–105. <https://doi.org/10.1101/gr.082701.108>

Fukuoka M, Yano S, Giaccone G, et al. (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. *J Clin Oncol*, 21: 2237–2246.

Gazdar AF, Minna JD. (2008). Deregulated EGFR signaling during lung cancer progression : mutations, amplicons, and autocrine loops. *Cancer Prev Res*, 1: 156–160.

Gazdar AF, Shigematsu H, Herz J, et al. (2004). Mutations and addiction to EGFR: the Achilles “heal” of lung cancers? *Trends Mol Med*, 10: 481–486.

Ge, H., Li, B., Hu, W. -X., Li, R. -J., Jin, H., Gao, M. -M., et al. (2015). MicroRNA-148b is down-regulated in non-small cell lung cancer and associated with poor survival. *International Journal of Clinical and Experimental Pathology*, [online] 8(1), pp.800–805. Available at: <https://www.ijcep.com/files/ijcep0002790.pdf> [Accessed 04 July 2018].

- Gerlinger M., Rowan A. J., Horswell S., et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N Engl J Med*, 366:883-92. <https://doi.org/10.1056/NEJMoa1113205>
- Goldstraw, P., Crowley, J., Chansky, K., Giroux, D., Groome, P., Rami-Porta, R., et al. (2007). The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. *Journal of Thoracic Oncology*, 2(8), pp.706-714. <https://doi.org/10.1097/JTO.0b013e31812f3c1a>
- Graham, J. C., Paul, S. S., Gregory, Y. H., Sean, T. K. (2002). The hypercoagulable state of malignancy: Pathogenesis and current debate. *Neoplasia*, 4(6):465-473. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC15503>.
- Greenman, C., Stephens, P., Smith, R., et al. (2007). Patterns of somatic mutation in human cancer genomes. *Nature*, 446: 153-8.
- Guengerich F. P., Shimada T. (1998). Activation of procarcinogens by human cytochrome P450 enzymes. *Mutat Res* 1998, 400:201–213.
- Guz, M., Rivero-Müller, A., Okoń, E., Stenzel-Bembenek, A., Polberg, K., Słomka, M., & Stepulak, A. (2014). MicroRNAs-Role in Lung Cancer. *Disease Markers*, 2014, p.218169. <https://doi.org/10.1155/2014/218169>
- Haber, D. A., Settleman, J. (2007). Cancer: drivers and passengers. *Nature*, 446: 145-6.
- Hecht SS. (1999). Tobacco smoke carcinogens and lung cancer. *J Natl Cancer Inst*, 91: 1194–1210.
- Hirsch F. R., Varella-Garcia M., Bunn PA Jr., et al. (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. *J Clin Oncol*, 21: 3798–3807.
- Hoffmann D, Hoffmann I, El-Bayoumy K. (2001). The less harmful cigarette: a controversial issue. a tribute to Ernst L. Wynder. *Chem Res Toxicol*, 14:767–790.
- Hofman V., Bonnetaud C., Ilie M. I., et al. (2011). Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. *Clin Cancer Res*, 17:827-35. <https://doi.org/10.1158/1078-0432.CCR-10-0445>
- Houlston, R. S. (2000). CYP1A1 polymorphisms and lung cancer risk: a meta-analysis. *Pharmacogenetics*, 10(2):105-114.

- Hukkanen J. (2012). Induction of cytochrome P450 enzymes: a view on human in vivo findings. *Expert Rev Clin Pharmacol*, 5:569–585.
- Ilie M., Hofman V., Long E., et al. (2014). Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? *Ann Transl Med*, 2:107.
- Ilie M., Long E., Butori C., et al. (2012). ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. *Ann Oncol*, 23:2907-13. <https://doi.org/10.1093/annonc/mds137>
- Ilie M., Hofman V., Long-Mira E., et al. (2014). "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. *PLoS One*, 9:e111597. <https://doi.org/10.1371/journal.pone.0111597>
- Ilonen I. 2011. Non-small cell lung cancer : studies on pathogenesis, tumor targetting, and treatment outcomes. Helsinki University Biomedical Dissertations No. Helsinki: University of Helsinki;. Available from: <https://helda.helsinki.fi/bitstream/handle/10138/26363/nonsmall.pdf?sequence=1>
- International Agency for Research of Cancer. (2018). GLOBOCAN 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. [online] Globocan.iarc.fr. Available at: https://globocan.iarc.fr/Pages/fact_sheets_population.aspx?%20country=360. [Accessed 23 Aug. 2018]
- International Agency for Research of Cancer. Tumors of the lung [cited 2014 January 12] Available from: <http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb10/bb10-chap1.pdf>.
- Imielinski, M., Berger, A. H., Hammerman, P. S., et al. (2012). Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell*, 150: 1107-20.
- Jamal-Hanjani, M., Wilson, G. A., Mc Granahan, N., et al. (2017). Tracking the Evolution of Non–Small-Cell Lung Cancer. *N Engl J Med*, 376: 2109-2121.
- Jänne P. A., Yang J. C., Kim D. W., et al. (2015). AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *N Engl J Med*, 372:1689-99. <https://doi.org/10.1056/NEJMoa1411817>
- Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., Forman, D., et al. (2011). Global cancer statistics. *CA Cancer J Clin*, 61:69–90.

- Jonsson, S., Thorsteinsdottir, U., Gudbjartsson, D. F., Jonsson, H. H., Kristjansson, K., Arnason, S., Gudnason, V., Isaksson, H. J., Hallgrimsson, J., Gulcher, J. R., Amundadottir, L. T., Kong, A., Stefansson, K. (2004). Familial risk of lung carcinoma in the Icelandic population. *Jama*, 292(24):2977-2983.
- Kiyohara, C., Yoshimasu, K. (2007). Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a metaanalysis. *Int J Med Sci*, 4(2):59-71.
- Kobayashi, S., Boggon T. J., Dayaram T., et al. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *New England Journal Medicine*, 352: 786–792.
- Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004). Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. *Cancer research*, 64(24), pp.8919-8923. <https://doi.org/10.1158/0008-5472.CAN-04-2818>
- Kosaka, N., Iguchi, H., & Ochiya, T. (2010). Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. *Cancer science*, 101(10), pp.2087–2092. <https://doi.org/10.1111/j.1349-7006.2010.01650.x>
- Kresno, S. B. 2011. Micro-RNA dan Implikasinya pada Kanker. *Ind. J. Cancer*, 5(3):119–27.
- Kris, M. G., Natale, R. B., Herbst, R. S., et al. (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. *JAMA*, 290: 2149–2158.
- Kubota, M., Sogawa, K., Kaizu, Y., et al. (1991). Xenobiotic responsive element in the 5'-upstream region of the human *P-450c* gene. *J Biochem*, 110:232–236.
- Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993). The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell*, 75(5), pp.843–854. [https://doi.org/10.1016/0092-8674\(93\)90529-Y](https://doi.org/10.1016/0092-8674(93)90529-Y)
- Li, X., Hemminki, K. (2004). Inherited predisposition to early onset lung cancer according to histological type. *Int J Cancer*, 112(3):451-457.
- Li, L., Chen, Y., Li, S., Huang, C., & Qin, Y. (2015). Expression of miR-148/152 Family as Potential Biomarkers in Non-Small-Cell Lung Cancer. *Medical Science Monitor*, 21, pp.1155–1161. <https://doi.org/10.12659/MSM.892940>

- Liu, W., Mao, S.-Y., & Zhu, W.-Y. (2007). Impact of tiny miRNAs on cancers. *World Journal of Gastroenterology: WJG*, **13**(4), pp.497–502. <https://doi.org/10.3748/wjg.v13.i4.497>
- Liu, L., Shao, X., Gao, W., Bai, J., Wang, R., Huang, P., et al. (2010). The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. *Journal of Thoracic Oncology*, **5**(12), pp.1922–1932. <https://doi.org/10.1097/JTO.0b013e3181f26266>
- Liu, G. -L., Liu, X., Lv, X. -B., Wang, X. -P., Fang, X. -S., & Sang, Y. (2014). miR-148b functions as a tumor suppressor in non-small cell lung cancer by targeting carcinoembryonic antigen (CEA). *International Journal of Clinical and Experimental Medicine*, [online] **7**(8), pp.1990–1999. Available at: <https://www.ijcem.com/files/ijcem0001093.pdf> [Accessed 05 July 2018]
- Luo, H., Liang C. (2018). MicroRNA-148b inhibits proliferation and the epithelial-mesenchymal transition and increases radiosensitivity in non-small cell lung carcinomas by regulating ROCK1. *Exp Ther Med*, **15**(4): 3609-3616. Doi: 10.3892/etm.2018.5845.
- Lodes, M. J., Caraballo, M., Suci, D., Munro, S., Kumar, A., & Anderson, B. (2009). Detection of Cancer with Serum miRNAs on an Oligonucleotide Microarray. *PLoS ONE*, **4**(7), p.e6229. <https://doi.org/10.1371/journal.pone.0006229>
- Lynch TJ, Bell DW, Sordella R, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med*, **350**: 2129–2139.
- Manning B. D., Cantley L. C. (2007). AKT/PKB signaling: navigating downstream. *Cell*, **129**, pp.1261-74.
- Marijon H, Bouyon A, Vignot S, et al. 2009. Facteurs pronostiques et predictifs des cancers bronchiques. *Bulletin du Cancer*, **96**: 391–404.
- Martin, B., Paesmans, M., Berghmans, T., Branle, F., Ghisdal, L., Mascaux, C., et al. (2003). Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. *British Journal of Cancer*, **89**(1), pp.55–64. <https://doi.org/10.1038/sj.bjc.6601095>
- Martin, B., Paesmans, M., Mascaux, C., Berghmans, T., Lothaire, P., Meert, A.-P., et al. (2004). Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. *British Journal of Cancer*, **91**(12), pp.2018–2025. <https://doi.org/10.1038/sj.bjc.6602233>

- Mascaux, C., Iannino, N., Martin, B., Paesmans, M., Berghmans, T., Dusart, M., et al. (2005). The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. *British Journal of Cancer*, **92**(1), pp.131–139. <https://doi.org/10.1038/sj.bjc.6602258>
- Matakidou, A., Eisen, T., Houlston, R. S.: TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis.
- Meert, A. -P., Martin, B., Paesmans, M., Berghmans, T., Mascaux, C., Verdebout, J.-M., et al. (2003). The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. *British Journal of Cancer*, **89**(6), pp.959–965. <https://doi.org/10.1038/sj.bjc.6601252>
- Meert, A., Paesmans, M., Martin, B., Delmotte, P., Berghmans, T., Verdebout, J. - M., et al. (2002). The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. *British Journal of Cancer*, **87**(7), pp.694–701. <https://doi.org/10.1038/sj.bjc.6600551>
- Meert, A., Martin, B., Delmotte, P., Berghmans, T., Lafitte, J. J., Mascaux, C., et al. (2002). The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. *European Respiratory Journal*, **20**(4), pp.975–981. <https://doi.org/10.1183/09031936.02.00296502>
- Mohammad, S., Stanley, N., Cardiac Potassium Channel Disorder, an issue of cardiac electrophysiology. Clinic review articles cardiac electrophysiology clinics, [online] **5**(1), pp.300-301. Available at: <https://books.google.co.id/books?id=yUpgDAAQBAJ> [Accessed 06 April 2019]
- Mok, T., Wu, Y. L., Lee, J. S., et al. (2015). Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. *Clin Cancer Res*, **21**:3196-203. <https://doi.org/10.1158/1078-0432.CCR-14-2594>
- Molina, J. R., Adjei, A. A. (2006). The Ras/Raf/MAPK pathway. *J Thorac Oncol*, **1**: 7–9.
- Molina-Vila, M. A., Mayo-de-las-Casas, C., Giménez-Capitán, A., et al. (2016). Liquid biopsy in non-small cell lung cancer. *Frontiers in Medicine*, **3**. <https://doi.org/10.3389/fmed.2016.00069>
- Moon, A. (2006). Differential functions of Ras for malignant phenotypic conversion. *Arch Pharm Res*, **29**: 113–122.

- Miller JA. (1998). The metabolism of xenobiotics to reactive electrophiles in chemical carcinogenesis and mutagenesis: a collaboration with Elizabeth Cavert Miller and our associates. *Drug Metab Rev*, 30:645–674.
- Murtaza, M., Dawson, S. J., Tsui, D. W., et al. (2013). Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. *Nature*, 497:108-12. <https://doi.org/10.1038/nature12065>
- Nakamura, H., Saji, H., Ogata, A., Hosaka, M., Hagiwara, M., Kawasaki, N., et al. (2002). Immunologic parameters as significant prognostic factors in lung cancer. *Lung Cancer*, 37(2), pp.161–169. [https://doi.org/10.1016/S0169-5002\(02\)00100-9](https://doi.org/10.1016/S0169-5002(02)00100-9)
- Naoki K, Chen TH, Richards WG, et al. (2002). Missense mutations of the BRAF gene in human lung adenocarcinoma. *Cancer Res*, 62: 7001–7003.
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Non-small cell lung cancer version I 2015. [ebook] Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf [Accessed 23 Aug. 2018]
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Non-small cell lung cancer version I 2017 [ebook]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf [Accessed 23 Aug. 2018]
- National Institutes of Health. National Cancer Institute: SEER Cancer Statistics Review 1973-2008.
- Nelson, K. M., & Weiss, G. J. (2008). MicroRNAs and cancer: past, present, and potential future. *Molecular cancer therapeutics*, 7(12), pp.3655–3660. <https://doi.org/10.1158/1535-7163.MCT-08-0586>
- Nicholson, R. I., Gee, J. M., Harper, M. E. (2001). EGFR and cancer prognosis. *Eur J Cancer*. 37: Suppl. 4, S9–S15.
- Nilsson, R. J., Karachaliou, N., Berenguer, J., et al. (2016). Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. *Oncotarget*, 7:1066-75.
- Osann, K. E. (1991). Lung cancer in women: the importance of smoking, family history of cancer, and medical history of respiratory disease. *Cancer Res*, 51(18):4893-4897.
- Paesmans, M. (2005). Facteurs pronostiques du cancer bronchique. *Revue des maladies respiratoires*, [online] 22(6), pp.76–80. Available at: <https://www.em-consulte.com/rmr/article/157304> [Accessed 5 July 2018]

- Paez JG, Janne PA, Lee JC, et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science*, 304: 1497–1500.
- Pak, M. G., Lee, C.-H., Lee, W.-J., Shin, D.-H., & Roh, M.-S. (2015). Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status. *Diagnostic Pathology*, **10**, p.99. <https://doi.org/10.1186/s13000-015-0339-4>
- Pao W, Miller V, Zakowski M, et al. (2004). EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci USA*, 101: 13306–13311.
- Pao W, Wang TY, Riely GJ, et al. (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. *PLoS Med*, 2: e17.
- Perhimpunan Dokter Paru Indonesia. (2003). Kanker Paru: Pedoman Diagnosis dan Penatalaksanaan di Indonesia. [ebook] Available from: <http://www.klikdpi.com/konsensus/konsensus-kankerparu/kankerparu.pdf> [Accessed 23 Aug. 2018]
- Perron, M. P., & Provost, P. (2008). Protein interactions and complexes in human microRNA biogenesis and function. *Frontiers in Bioscience*, [online] **13**, 2537–2547. Available at: <https://www.bioscience.org/2008/v13/af/2865/fulltext.htm> [Accessed 05 July 2018]
- Poliseno L., Salmena L., Riccardi L., et al. (2010). Identification of the miR-106b-25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its HostGene MCM7 in Transformation. *Sci Signal*, **3**, pp.1-26.
- Piotrowska, Z., Niederst, M. J., Karlovich, C. A., et al. (2015). Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. *Cancer Discov*, 5:713-22. <https://doi.org/10.1158/2159-8290.CD-15-0399>
- Pujol, J.-L., Molinier, O., Ebert, W., Daurès, J.-P., Barlesi, F., Bucchieri, G., et al. (2004). CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. *British Journal of Cancer*, **90**(11), 2097–2105. <https://doi.org/10.1038/sj.bjc.6601851>

- Raimondi, S., Paracchini, V., Autrup, H., Barros-Dios, J. M., Benhamou, S., Boffetta, P., et al. (2006). Meta and pooled analysis of GSTT1 and lung cancer: a HuGE-GSEC review. *Am J Epidemiol*, 164(11):1027-1042.
- Rajewsky, N. (2006). L (ou) sy miRNA targets?. *Nature Structural and Molecular Biology*, 13(9), 754–755. <https://doi.org/10.1038/nsmb0906-754> (keterangan: tidak ada jurnal fisik, category: comment, news)
- Rajewsky, N. (2006). microRNA target predictions in animals. *Nature Genetics*, 38(6s), pp.S8-S13. <https://doi.org/10.1038/ng1798>
- Riely, G. J., Pao, W., Pham, D., Li, A. R., Rizvi, N., Venkatraman, E. S., et al. (2006). Clinical course of patients with non–small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. *Clinical cancer research*, 12(3), pp.839-844. <https://doi.org/10.1158/1078-0432.CCR-05-1846>
- Risch, N., Merikangas, K. (1996). The future of genetic studies of complex human diseases. *Science*, 273(5281):1516-1517.
- Robinson, D. R., Wu, Y. M., Lin, S. F. (2000). The protein tyrosine kinase family of the human genome. *Oncogene*, 19: 5548–5557.
- Rowinsky, E. K. (2004). The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. *Annu Rev Med*, 55: 433–457.
- Russell, P. A., Wainer, Z., Wright, G. M., Daniels, M., Conron, M., & Williams, R. A. (2011). Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. *Journal of Thoracic Oncology*, 6(9), pp.1496–1504. <https://doi.org/10.1097/JTO.0b013e318221f701>
- Sacher, A. G., Paweletz, C., Dahlberg, S. E., et al. (2016). Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. *JAMA Oncol*, 2:1014-22. <https://doi.org/10.1001/jamaoncol.2016.0173>
- Saito, M., Schetter, A. J., Mollerup, S., Kohno, T., Skaug, V., Bowman, E. D., et al. (2011). The association of microRNA expression with prognosis and progression in early stage, non small cell lung adenocarcinoma: a retrospective analysis of three cohorts. *Clinical Cancer Research*, 17(7), pp.1875–1882. <http://doi.org/10.1158/1078-0432.CCR-10-2961>

- Salmena L., Carracedo A., Pandolfi P. P. (2008). Tenets of PTEN tumor suppression. *Cell*, **133**, pp.403-14
- Samuels Y, Wang Z, Bardelli A, et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. *Science*, 304: 554.
- Sasaki, J. (2013). Compounds in tobacco smoke and pathogenesis of the diseases. *Nihon Rinsho*, 71:383–389.
- Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., et al. (2002). Comparision of four chemotherapy regimens for advanced NSCLC. *N Eng J Med*, 346:92–8.
- Sharma, S. V., Bell, D. W., Settleman, J., et al. (2007). Epidermal growth factor receptor mutations in lung cancer. *Nat Rev Cancer*, 7: 169–181.
- Shaw, G. L., Falk, R. T., Pickle, L. W., Mason, T. J., Buffler, P. A. (1991). Lung cancer risk associated with cancer in relatives. *J Clin Epidemiol*, 44(4-5):429-437.
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. (2005). Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med*, 353: 123–132.
- Shepherd FA, Rosell R. (2007). Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. *J Thorac Oncol*, 2: Suppl. 2, S68–S76.
- Shigematsu H, Gazdar AF. (2006). Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. *Int. J. Cancer*, 118: 257–262.
- Shigematsu H, Lin L, Takahashi T, et al. (2005). Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Cancer Inst*, 97: 339–346.
- Shigematsu H, Takahashi T, Nomura M, et al. (2005). Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. *Cancer Res*, 65: 1642–1646.
- Soung YH, Lee JW, Kim SY, et al. (2006). Somatic mutations of the ERBB4 kinase domain in human cancers. *Int J Cancer*, 118: 1426–1429.
- Surgeon General Report. (2014). Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion. Available at: <http://www.surgeongeneral.gov/library/reports/50-years-of-progress>.
- Stanczyk, J., Pedrioli, D. M. L., Brentano, F., Sanchez- Pernaute, O., Kolling, C., Gay, R. E., et al. (2008). Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. *Arthritis & Rheumatism*, **58**(4), pp.1001–1009. <https://doi.org/10.1002/art.23386>

- Steels, E., Paesmans, M., Berghmans, T., Branle, F., Lemaitre, F., Mascaux, et al. (2001). Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. *European Respiratory Journal*, [online] **18**(4), pp.705–719. Available at: <https://erj.ersjournals.com/content/18/4/705> [Accessed 05 July 2018]
- Sun S, Schiller JH, Gazdar AF. (2007). Lung cancer in never smokers—a different disease. *NatRev Cancer*, 7: 778–790.
- Sundaresan, T. K., Sequist, L. V., Heymach, J.V., et al. (2016). Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. *Clin Cancer Res*, 22:1103-10. <https://doi.org/10.1158/1078-0432.CCR-15-1031>
- Surveillance, Epidemiology, and End Results Program. (2018). *Lung and Bronchus Cancer - Cancer Stat Facts*. [online] Seer.cancer.gov. Available at: <https://seer.cancer.gov/statfacts/html/lungb.html> [Accessed 23 Aug. 2018].
- Swanson, H. I., Chan, W. K., Bradfield, C. A. (1995). DNA binding specificities and pairing rules of the Ah receptor, ARNT, and SIM proteins. *J Biol Chem*, 270:26292–26302.
- Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., et al. (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. *Cancer research*, **64**(11), pp.3753–3756. <https://doi.org/10.1158/0008-5472.CAN-04-0637>
- Tomita, M., Shimizu, T., Hara, M., Ayabe, T., Onitsuka, T. (2009). Preoperative leukocytosis, anemia and thrombocytosis are associated with poor survival in non-small cell lung cancer. *Anticancer Res*, 29(7),2687-90. <http://www.ncbi.nlm.nih.gov/pubmed/19596947>
- Tsugane, S., Watanabe, S., Sugimura, H., Arimoto, H., Shimosato, Y., Suemasu, K. (1987). Smoking, occupation and family history in lung cancer patients under fifty years of age. *Jpn J Clin Oncol*, 17(4):309-317.
- Uramoto H, Mitsudomi T. (2007). Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? *Br J Cancer*, 96: 857–863.
- Vollmer RT, Govindan R, Graziano SL, et al. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. *Clin Cancer Res*. 2003; 9(5): 1728-33.
- White RH. Identifying risk factors for venous thromboembolism. *Circulation*. 2012;125:2051-3.

- Wightman, B., Ha, I., & Ruvkun, G. (1993). Posttranscriptional regulation of the heterochronic gene *lin-14* by *lin-4* mediates temporal pattern formation in *C. elegans*. *Cell*, **75**(5), pp.855–862. [https://doi.org/10.1016/0092-8674\(93\)90530-4](https://doi.org/10.1016/0092-8674(93)90530-4)
- Wong, S. Q., Li, J., Tan, A. Y., et al. (2014). Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. *BMC Med Genomics*, **7**:23. <https://doi.org/10.1186/1755-8794-7-23>
- Wu, A. H., Yu, M. C., Thomas, D. C., Pike, M. C., Henderson, B. E. (1988). Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. *Cancer Res*, **48**(24 Pt 1):7279-7284.
- Wu, J. Y., Wu, S. G., Yang, C. H., et al. (2008). Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. *Clin Cancer Res*, **14**: 4877–4882.
- Wu, W., Zhao, S. (2013). Metabolic changes in cancer: beyond the Warburg effect. *Acta Biochim Biophys Sin*, **45**: 18-26. Doi: 10.1093/abbs/gms104.
- Yamamoto, H., Shigematsu, H., Nomura, M., et al. (2008). PIK3CA mutations and copy number gains in human lung cancers. *Cancer Res*, **68**: 6913–6921.
- Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. *Cancer cell*, **9**(3), pp.189–198. <https://doi.org/10.1016/j.ccr.2006.01.025>
- Yang, M., Shen, H., Qiu, C., Ni, Y., Wang, L., Dong, W., et al. (2013). High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. *European journal of cancer*, **49**(3), pp.604–615. <https://doi.org/10.1016/j.ejca.2012.09.031>
- Yang, Y., Chen K., Zhou Y., Hu Z., Chen S., Huang Y. (2018). Application of serum microRNA-9-5p, 21-5p, and 223-3p combined with tumor markers in the diagnosis of non-small-cell lung cancer in Yunnan in southwestern China. *Onco Targets and Ther*, **11**: 587-597. Doi: 10.2147/OTT.S152957
- Ying, J., Li, Z., Fang, P. (2013). Prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer. *Clinics* (Sao Paulo), **68**(5):686-693. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654299/>.
- Yonesaka, K., Zejnullahu, K., Lindeman, N., et al. (2008). Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. *Clin Cancer Res*, **14**: 6963–6973.

- Zang, Y. S., Zhong, Y. F., Fang, Z., Li, B., & An, J. (2012). MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. *Cancer gene therapy*, **19**(11), pp.773–778. <https://doi.org/10.1038/cgt.2012.60>
- Zhang, J., Iwanaga, K., Choi, K. C., et al. (2008). Intratumoral epiregulin is a marker of advanced disease in non small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. *Cancer Prev Res*, 1: 201–207.
- Zhou, B. B., Peyton, M., He, B., et al. (2006). Targeting ADAMmediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. *Cancer Cell*, 10: 39–50.
- Zhu, C. Q., da Cunha, S. G., Ding, K., et al. (2008). Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. *J Clin Oncol*, 26: 4268–4275.